The Clinical Innovation Zone welcomes new tenants
The University of Glasgow Clinical Innovation Zone is delighted to welcome two new tenants - the West of Scotland Innovation Hub and AstraZeneca. The close proximity to clinical expertise and innovation and access to the existing infrastructure, within a highly supportive and flexible ecosystem were key factors in the decision to locate within the Clinical Innovation Zone at the Queen Elizabeth University Hospital campus.
The West of Scotland Innovation Hub is a part of the NHS and draws in expertise across eHealth, R&D and clinical areas. The focus of the West of Scotland Innovation Hub is to promote innovation across the 5 NHS boards spanning Ayrshire & Arran, Dumfries & Galloway, Forth Valley, Greater Glasgow & Clyde and Lanarkshire. They work with a number of companies, both SMEs and larger multinational companies with a focus to improve healthcare across the NHS whilst fitting in with regional and national agendas.
AstraZeneca is a global pharmaceutical company who are continually investing in UK business and are an integral part of the scientific community focussing on high value R&D activities. AstraZeneca work alongside the NHS, government, patient groups and other UK healthcare professionals.
In addition to the new tenants, two existing tenants, BioClavis and MR CoilTech have expanded their footprint within the Clinical Innovation Zone as a result of the growth of the companies.
Dr Carol Clugston, Chief Operating Officer/Director of Professional Services, College of Medical, Veterinary & Life Sciences said: “It is fantastic to see that the CIZ continues to attract local and international organisations whilst supporting expansion plans for existing tenants. We’re enthusiastic about our future potential to support and implement our ‘triple-helix’ approach, fostering collaboration to drive innovation and harness precision medicine as a disruptive force to deliver the right treatment to the right patient at the right time”.
First published: 6 December 2019